Truist raised the firm’s price target on Stryker (SYK) to $415 from $410 and keeps a Hold rating on the shares. The company delivered another solid double-digit revenue and EPS beat and raise, and while there were some “small nits to pick” around NARI destocking, softer knee growth, and longer than expected Medical supply constraints, these are seen as “transient”, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker Corp’s Earnings Call Highlights Robust Growth
- Stryker price target raised to $438 from $421 at UBS
- Stryker price target raised to $450 from $436 at Baird
- Stryker’s Strong Performance and Growth Potential Justifies Buy Rating Despite High Valuation
- Stryker’s Strong Financial Performance and Strategic Initiatives Lead to Buy Rating